🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Richard Ghalie

MEI Pharma (United States)

ORCID: 0000-0001-6882-8179

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies”.

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Blood Advances(2024)10.1182/bloodadvances.2024014633

N/A

0.420DataRank · unranked

9 citations

Danielle M. Brander, Yesid Alvarado, Catherine Diefenbach, Daniel Nathan Egan, Shira Dinner +14 more

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100108

N/A

0.173DataRank · unranked

2 citations

Rachel J. Cook, Shira Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi‐Sharifi +9 more

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

British Journal of Haematology(2024)10.1111/bjh.19419

N/A

0DataRank · unranked

5 citations

Catherine Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L. Tsai +11 more